Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Liabilities from Discontinued Operations (2022 - 2025)

Historic Liabilities from Discontinued Operations for Precision Biosciences (DTIL) over the last 4 years, with Q3 2025 value amounting to $885000.0.

  • Precision Biosciences' Liabilities from Discontinued Operations fell 3213.19% to $885000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $885000.0, marking a year-over-year decrease of 3213.19%. This contributed to the annual value of $1.2 million for FY2024, which is 5208.91% down from last year.
  • According to the latest figures from Q3 2025, Precision Biosciences' Liabilities from Discontinued Operations is $885000.0, which was down 3213.19% from $885000.0 recorded in Q2 2025.
  • Precision Biosciences' 5-year Liabilities from Discontinued Operations high stood at $3.5 million for Q4 2022, and its period low was $885000.0 during Q1 2025.
  • Over the past 4 years, Precision Biosciences' median Liabilities from Discontinued Operations value was $1.3 million (recorded in 2024), while the average stood at $1.6 million.
  • The largest annual percentage gain for Precision Biosciences' Liabilities from Discontinued Operations in the last 5 years was 2053.63% (2024), contrasted with its biggest fall of 5208.91% (2024).
  • Over the past 4 years, Precision Biosciences' Liabilities from Discontinued Operations (Quarter) stood at $3.5 million in 2022, then decreased by 27.47% to $2.5 million in 2023, then crashed by 52.09% to $1.2 million in 2024, then dropped by 26.5% to $885000.0 in 2025.
  • Its Liabilities from Discontinued Operations was $885000.0 in Q3 2025, compared to $885000.0 in Q2 2025 and $885000.0 in Q1 2025.